These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31119740)

  • 1. Distinct mutational landscape of inverted urothelial papilloma.
    Akgul M; MacLennan GT; Cheng L
    J Pathol; 2019 Sep; 249(1):3-5. PubMed ID: 31119740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
    Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
    J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
    [No Abstract]   [Full Text] [Related]  

  • 6. RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder.
    Kitahama K; Shigematsu Y; Amori G; Sugawara E; Yonese J; Shibahara J; Takeuchi K; Inamura K
    Am J Surg Pathol; 2024 Apr; 48(4):458-464. PubMed ID: 38145408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.
    Lott S; Wang M; Zhang S; MacLennan GT; Lopez-Beltran A; Montironi R; Sung MT; Tan PH; Cheng L
    Mod Pathol; 2009 May; 22(5):627-32. PubMed ID: 19287463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent FGFR3 mutations in urothelial papilloma.
    van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
    J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HRAS mutations are frequent in inverted urothelial neoplasms.
    McDaniel AS; Zhai Y; Cho KR; Dhanasekaran SM; Montgomery JS; Palapattu G; Siddiqui J; Morgan T; Alva A; Weizer A; Lee CT; Chinnaiyan AM; Quist MJ; Grasso CS; Tomlins SA; Mehra R
    Hum Pathol; 2014 Sep; 45(9):1957-65. PubMed ID: 25097040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
    Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
    Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients.
    Picozzi S; Casellato S; Bozzini G; Ratti D; Macchi A; Rubino B; Pace G; Carmignani L
    Urol Oncol; 2013 Nov; 31(8):1584-90. PubMed ID: 22520573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverted papillomas of the prostatic urethra.
    Fine SW; Chan TY; Epstein JI
    Am J Surg Pathol; 2006 Aug; 30(8):975-9. PubMed ID: 16861968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
    Paner GP; Zehnder P; Amin AM; Husain AN; Desai MM
    Adv Anat Pathol; 2011 Jan; 18(1):79-89. PubMed ID: 21169741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?
    Cheville JC; Wu K; Sebo TJ; Cheng L; Riehle D; Lohse CM; Shane V
    Cancer; 2000 Feb; 88(3):632-6. PubMed ID: 10649258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.